Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies-Reference-Cited by-同舟云学术

Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies

Published:2011-07 Issue:7 Volume:216 Page:782-792
ISSN:0171-2985
Container-title:Immunobiology
language:en
Short-container-title:Immunobiology

Author:

Atassi M. Zouhair,Dolimbek Behzod Z.,Jankovic Joseph,Steward Lance E.,Aoki K. Roger

Publisher

Elsevier BV

Subject

Hematology,Immunology,Immunology and Allergy

Reference56 articles.

1. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1–A4;Arndt;J. Mol. Biol.,2006

2. Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking or protein binding sites;Atassi;Eur. J. Biochem.,1984

3. Basic immunological aspects of botulinum toxin therapy;Atassi;Mov. Disord.,2004

4. Mapping of the antibody-binding profile on botulinum neurotoxin A HN-domain (residues 449–859) with anti-toxin antibodies from four host species. Antigenic profile of the entire H-chain of botulinum neurotoxin A;Atassi;Protein J.,2004

5. Structure, activity and immune (T and B cell) recognition of botulinum neurotoxin;Atassi;Crit. Rev. Immunol.,1999

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Pseudo”-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study;Toxins;2023-10-18

2. No Secondary Treatment Failure during Incobotulinumtoxin—A Long-Term Treatment Demonstrated by the Drawing of Disease Severity;Toxins;2023-07-12

3. Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines;Aesthetic Surgery Journal;2023-04-13

4. Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials;Toxins;2023-01-10

5. Functional Deimmunization of Botulinum Neurotoxin Protease Domain via Computationally Driven Library Design and Ultrahigh-Throughput Screening;ACS Synthetic Biology;2023-01-09